[go: up one dir, main page]

WO2015137501A1 - レチノイン酸産生剤 - Google Patents

レチノイン酸産生剤 Download PDF

Info

Publication number
WO2015137501A1
WO2015137501A1 PCT/JP2015/057560 JP2015057560W WO2015137501A1 WO 2015137501 A1 WO2015137501 A1 WO 2015137501A1 JP 2015057560 W JP2015057560 W JP 2015057560W WO 2015137501 A1 WO2015137501 A1 WO 2015137501A1
Authority
WO
WIPO (PCT)
Prior art keywords
retinoic acid
lactic acid
present
producing agent
immune function
Prior art date
Application number
PCT/JP2015/057560
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
幸夫 浅見
宏 狩野
聖也 牧野
伊藤　裕之
敏志 八村
優 田之倉
宮川　拓也
知賢 朴
Original Assignee
株式会社明治
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社明治 filed Critical 株式会社明治
Priority to SG11201607674SA priority Critical patent/SG11201607674SA/en
Priority to CN201580013813.7A priority patent/CN106102755B/zh
Priority to JP2016507856A priority patent/JP6543614B2/ja
Publication of WO2015137501A1 publication Critical patent/WO2015137501A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Definitions

  • the present invention can provide an agent capable of strongly inducing the self-biological defense function in the body by promoting production of retinoic acid.
  • Lactobacillus delbruecki subspecies bulgaricus OLL1073R-1 strain is under the accession number FERM BP-1074, the National Institute of Technology and Evaluation (NITE-IPOD) (Kitsutsu, Chiba, Japan) The city has been deposited internationally under the Budapest Treaty on February 22, 1999 (original deposit date). This strain was transferred from a domestic deposit to an international deposit on November 29, 2006.
  • the lactic acid bacteria used in the present invention may be either live or dead cells.
  • the lactic acid bacteria used in the present invention may be frozen or lyophilized.
  • the lactic acid bacterium used in the present invention may be only lactic acid bacteria, but in a form containing components other than the lactic acid bacteria (for example, a cryoprotectant or a freeze-drying protectant). It may be in a state where it is dispersed in various media such as water and starch that have been used in pharmaceutical materials and food materials.
  • the present invention also includes parenteral administration of the retinoic acid producing agent according to the present invention to the skin or the like, for example, a whitening method based on a whitening action (a prevention or treatment method or a cosmetic method) disclosed in Patent Document 1 Also provide.
  • the administration target of the retinoic acid producing agent of the present invention is preferably an animal such as a mammal, particularly an elderly person or an elderly mammal.
  • pylori Bacteria translocation, persistence of inflammation of the intestinal mucosa, changes in the balance of intestinal flora (such as disruption of the balance of intestinal flora), and diseases derived from these inflammations, Examples include Crohn's disease, inflammatory colitis such as ulcerative colitis, excessive inflammation and allergic symptoms.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PCT/JP2015/057560 2014-03-14 2015-03-13 レチノイン酸産生剤 WO2015137501A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SG11201607674SA SG11201607674SA (en) 2014-03-14 2015-03-13 Retinoic-acid-producing agent
CN201580013813.7A CN106102755B (zh) 2014-03-14 2015-03-13 用于产生视黄酸的试剂
JP2016507856A JP6543614B2 (ja) 2014-03-14 2015-03-13 レチノイン酸産生剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014-051065 2014-03-14
JP2014051065 2014-03-14

Publications (1)

Publication Number Publication Date
WO2015137501A1 true WO2015137501A1 (ja) 2015-09-17

Family

ID=54071936

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2015/057560 WO2015137501A1 (ja) 2014-03-14 2015-03-13 レチノイン酸産生剤

Country Status (5)

Country Link
JP (1) JP6543614B2 (zh)
CN (1) CN106102755B (zh)
HK (1) HK1226296A1 (zh)
SG (1) SG11201607674SA (zh)
WO (1) WO2015137501A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019011314A (ja) * 2017-06-29 2019-01-24 京都府公立大学法人 制御性ｔ細胞誘導剤、アジュバント及び食品組成物
WO2022075096A1 (ja) * 2020-10-07 2022-04-14 株式会社 資生堂 Ｒａｌｄｈ２発現増強剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201407677WA (en) * 2009-11-25 2015-01-29 Meiji Co Ltd Antiviral agent and food/beverage composition
JP5571941B2 (ja) * 2009-12-14 2014-08-13 雪印メグミルク株式会社 制御性ｔ細胞増加剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AYA YOKOTA: "Regulation of lymphocyte trafficking by retinoic acid-producing dendritic cells in the intestine", CLINICAL IMMUNOLOGY & ALLERGOLOGY, vol. 55, no. 4, 2011, pages 454 - 459 *
KEN UKIBE ET AL.: "Lactobacillus gasseri SBT2055 ni yoru Chokan deno IgA Sansei Yudo to sono Kiko Kaimei", JOURNAL OF INTESTINAL MICROBIOLOGY, vol. 26, no. 2, 2012, pages 94 *
SATOSHI ARAI ET AL.: "Nyusankin Lactobacillus paracasei MCC1849 ni yoru IgA Sansei Sokushin Sayo to Kansen Bogyo Sayo", JAPAN SOCIETY FOR BIOSCIENCE, BIOTECHNOLOGY, AND AGROCHEMISTRY TAIKAI KOEN YOSHISHU, 2014, Retrieved from the Internet <URL:http://www.jsbba.or.jp/MeetingofJSBBA/2014/meeting_of_jsbba_2014.html> [retrieved on 20150525] *
SHUJI IKEGAMI ET AL.: "Probiotics Kino Kenkyu no Shintenkai, Immunomodulating effects on EPS (exopolysaccharides) produced by Lactobacillus bulgaricus", THE FOOD INDUSTRY, vol. 53, no. 2, 2009, pages 36 - 43 *
TADAOMI KAWASHIMA ET AL.: "Lactobacillus plantarum YU -kabu ni yoru Chonai Saikinso Kaizen to IgA Sansei Zokyo", JOURNAL OF JAPAN SOCIETY FOR LACTIC ACID BACTERIA, vol. 20, no. 2, 2009, pages 62 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019011314A (ja) * 2017-06-29 2019-01-24 京都府公立大学法人 制御性ｔ細胞誘導剤、アジュバント及び食品組成物
WO2022075096A1 (ja) * 2020-10-07 2022-04-14 株式会社 資生堂 Ｒａｌｄｈ２発現増強剤

Also Published As

Publication number Publication date
CN106102755A (zh) 2016-11-09
SG11201607674SA (en) 2016-11-29
JP6543614B2 (ja) 2019-07-10
JPWO2015137501A1 (ja) 2017-04-06
CN106102755B (zh) 2020-02-21
HK1226296A1 (zh) 2017-09-29

Similar Documents

Publication Publication Date Title
Ayichew et al. Bacterial probiotics their importances and limitations: a review
Franz et al. Enterococci as probiotics and their implications in food safety
JP5718916B2 (ja) 新規なラクトバチルス・プランタラム及びこれを含む組成物
Ait-Belgnaoui et al. Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction
JP5709883B2 (ja) 新規なラクトバチルス・プランタラム及びこれを含む組成物
JP5710250B2 (ja) 哺乳類乳汁微生物、それらを含有する組成物および乳腺炎の治療のためのそれらの使用
Getachew A review on effects of probiotic supplementation in poultry performance and cholesterol levels of egg and meat
Castillo et al. Probiotics: an alternative strategy for combating salmonellosis: immune mechanisms involved
Capcarova et al. The effect of selected microbial strains on internal milieu of broiler chickens after peroral administration
JP2012510291A (ja) 新規なラクトバチルス・プランタラム及びこれを含む組成物
MX2013005371A (es) Micro-organismos probioticos no replicantes que protegen contra las infecciones del tracto respiratorio superior.
Peivasteh-Roudsari et al. Probiotics and food safety: an evidence-based review
RU2439145C2 (ru) Штамм микроорганизма bacillus smithii tbmi12 mscl p737 и применение его в качестве пищевой или кормовой добавки, или компонента пробиотической композиции и пробиотическая композиция
BRPI0417793B1 (pt) composição compreendendo bifidobactéria globosum probiótica canina
Al-Yami et al. Lactobacillus species as probiotics: isolation sources and health benefits
US20250032564A1 (en) Strains, compositions and methods of use
Parichat et al. Probiotics: Sources, selection and health benefits
TW201902499A (zh) 用於類鐸受體２活性化之組成物
KR20240130711A (ko) 불안 장애의 치료 및/또는 예방에 있어서 포스트바이오틱스의 용도
Onyenweaku et al. Research Article Health Benefits of Probiotics
JP6543614B2 (ja) レチノイン酸産生剤
WO2011107960A1 (en) Compositions comprising lactobacillus mucosae for medical use
WO2015087919A1 (ja) 抗菌ペプチド誘導剤
KR101518445B1 (ko) 장관면역 조정제
JP2014166972A (ja) 腸炎抑制剤及び飲食品

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15761932

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2016507856

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15761932

Country of ref document: EP

Kind code of ref document: A1